SCHEMBL10043745

SCHEMBL10043745

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3ccc(F)cn3)ccc1C)c(=O)n2C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
AHR P35869 2/20 0.41
GRM4 Q14833 4/20 0.41
MAPK14 Q16539 5/20 0.40
BACE1 P56817 5/20 0.39
BACE2 Q9Y5Z0 2/20 0.39
CYP2D6 P10635 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043744 0.90 SYK (0.44) SYKNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL10043666 0.88 SYK (0.49) SYKALDH1A1MAPK14POLBMAPT
SCHEMBL10043679 0.88 SYK (0.47) SYKNPC1RAB9ASMN1; SMN2GAA
SCHEMBL10043922 0.86 MAPK14 (0.48) SYKNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL10043746 0.86 GRM4 (0.48) SYKNPC1RAB9ASMN1; SMN2GAA
SCHEMBL10043750 0.85 SYK (0.49) SYKALDH1A1MAPK14POLBMAPT
SCHEMBL10043707 0.85 SYK (0.43) SYKNPC1RAB9ASMN1; SMN2GAA
SCHEMBL10043691 0.85 NPC1 (0.48) SYKNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL10043739 0.85 SYK (0.46) SYKALDH1A1GAAAHRMAPK14
SCHEMBL10043869 0.84 GAA (0.45) SYKNPC1RAB9AGAAAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885NPC1 4095/4885RAB9A 1818/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885NPC1 4095/4885RAB9A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.